Thyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992–2006
Abstract
Background: The increasing incidence of thyroid cancer in the United States is well documented. In this study, we assessed the incidence patterns by histologic type according to demographic and tumor characteristics to further our understanding of these cancers.
Methods: We used the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program for cases diagnosed during 1992–2006 to investigate patterns for the four major histologic types of thyroid cancer by gender, race/ethnicity, and age as well as registry, tumor stage, and size.
Results: Among women, papillary thyroid cancer rates were highest among Asians (10.96 per 100,000 woman-years) and lowest among blacks (4.90 per 100,000 woman-years); follicular cancer rates did not vary substantially by race/ethnicity (p-values >0.05), medullary cancer rates were highest among Hispanics (0.21 per 100,000 woman-years) and whites (0.22 per 100,000 woman-years), and anaplastic rates were highest among Hispanics (0.17 per 100,000 woman-years). Among men, both papillary and follicular thyroid cancer rates were highest among whites (3.58 and 0.58 per 100,000 man-years, respectively), medullary cancer rates were highest among Hispanics (0.18 per 100,000 man-years), and anaplastic rates were highest among Asians (0.11 per 100,000 man-years). Racial/ethnic-specific rates did not vary notably across registries. In contrast to age-specific rates of papillary thyroid cancer that peaked in midlife (age 50), especially pronounced among women, rates for follicular, medullary, and anaplastic types continued to rise across virtually the entire age range, especially for anaplastic carcinomas. Female-to-male incidence rate ratios among whites decreased with age most steeply for the follicular type and least steeply for the medullary type; it was <1 until the very oldest ages for the anaplastic type.
Conclusion: We conclude that the similar age-specific patterns and lack of geographical variation across the SEER racial/ethnic groups indicate that detection effects cannot completely explain the observed thyroid cancer incidence patterns as variation in the amount or quality of healthcare provided has been shown to vary by SEER racial/ethnic groups, gender, and age. We find that the variations in age-specific patterns by gender and across histologic types are intriguing and recommend that future etiologic investigation focus on exogenous and endogenous exposures that are experienced similarly by racial/ethnic groups, more strongly among women, and distinctively by age.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Kilfoy BADevesa SSWard MHZhang YRosenberg PSHolford TRAnderson WF2009. Gender is an age-specific effect modifier for papillary cancers of the thyroid glandCancer Epidemiol Biomarkers Prev181092-1100. 1. Kilfoy BA, Devesa SS, Ward MH, Zhang Y, Rosenberg PS, Holford TR, Anderson WF 2009 Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Biomarkers Prev 18:1092–1100.
2.
Kilfoy BAZheng THolford TRHan XWard MHSjodin AZhang YBai YZhu CGuo GLRothman NZhang Y2009. International patterns and trends in thyroid cancer incidence, 1973–2002Cancer Causes Control20525-531. 2. Kilfoy BA, Zheng T, Holford TR, Han X, Ward MH, Sjodin A, Zhang Y, Bai Y, Zhu C, Guo GL, Rothman N, Zhang Y 2009 International patterns and trends in thyroid cancer incidence, 1973–2002. Cancer Causes Control 20:525–531.
3.
Davies LWelch HG2006. Increasing incidence of thyroid cancer in the United States, 1973–2002JAMA2952164-2167. 3. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295:2164–2167.
4.
Enewold LZhu KRon EMarrogi AJStojadinovic APeoples GEDevesa SS2009. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005Cancer Epidemiol Biomarkers Prev18784-791. 4. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, Devesa SS 2009 Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev 18:784–791.
5.
Liu SSemenciw RUgnat AMMao Y2001. Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effectsBr J Cancer851335-1339. 5. Liu S, Semenciw R, Ugnat AM, Mao Y 2001 Increasing thyroid cancer incidence in Canada, 1970–1996: time trends and age-period-cohort effects. Br J Cancer 85:1335–1339.
6.
Reynolds RMWeir JStockton DLBrewster DHSandeep TCStrachan MW2005. Changing trends in incidence and mortality of thyroid cancer in ScotlandClin Endocrinol62156-162. 6. Reynolds RM, Weir J, Stockton DL, Brewster DH, Sandeep TC, Strachan MW 2005 Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol 62:156–162.
7.
Albores-Saavedra JHenson DEGlazer ESchwartz AM2007. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype—papillary, follicular, and anaplastic: a morphological and epidemiological studyEndocr Pathol181-7. 7. Albores-Saavedra J, Henson DE, Glazer E, Schwartz AM 2007 Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype—papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr Pathol 18:1–7.
8.
Yu GChun-Lun Li JBranovan DMcCormick SSchantz SP2010. Thyroid cancer incidence and survival in the National Cancer Institute surveillance, epidemiology, and end results race/ethnicity groupsThyroid20465-473. 8. Yu G, Chun-Lun Li J, Branovan D, McCormick S, Schantz SP 2010 Thyroid cancer incidence and survival in the National Cancer Institute surveillance, epidemiology, and end results race/ethnicity groups. Thyroid 20:465–473.
9.
Howell E2001. The impact of the Medicaid expansions for pregnant women: a synthesis of the evidenceMed Care Res Rev583-30. 9. Howell E 2001 The impact of the Medicaid expansions for pregnant women: a synthesis of the evidence. Med Care Res Rev 58:3–30.
10.
Surveillance, Epidemiology, End Results (SEER) Program(November 2008 submission.) Public-Use Database (1973–2006), National Cancer Institute DCCPS, Surveillance Research Program, Cancer Statistics Branch, Released April 2009, based on the November 2008 submission. 10. Surveillance, Epidemiology, and End Results (SEER) Program. (November 2008 submission.) Public-Use Database (1973–2006), National Cancer Institute DCCPS, Surveillance Research Program, Cancer Statistics Branch, Released April 2009, based on the November 2008 submission.
11.
World Health Organization2000International Classification of Diseases for OncologyThirdWHOGeneva. 11. World Health Organization 2000 International Classification of Diseases for Oncology. Third edition. WHO, Geneva.
12.
Surveillance Research Program2009National Cancer Institute SEER*Stat softwarewww.seer.cancer.gov/seerstatversion 6.4.4. 12. Surveillance Research Program. 2009 National Cancer Institute SEER*Stat software. Available at www.seer.cancer.gov/seerstat, version 6.4.4.
13.
Fay MP. Approximate confidence intervals for rate ratios from directly standardized rates with sparse dataCommun Stat Theory Methods282141-2160. 13. Fay MP. Approximate confidence intervals for rate ratios from directly standardized rates with sparse data. Commun Stat Theory Methods 28:2141–2160.
14.
Fay MPTiwari RCFeuer EJZou Z2006. Estimating average annual percent change for disease rates without assuming constant changeBiometrics62847-854. 14. Fay MP, Tiwari RC, Feuer EJ, Zou Z 2006 Estimating average annual percent change for disease rates without assuming constant change. Biometrics 62:847–854.
15.
Devesa SSDonaldson JFears T1995. Graphical presentation of trends in ratesAm J Epidemiol141300-304. 15. Devesa SS, Donaldson J, Fears T 1995 Graphical presentation of trends in rates. Am J Epidemiol 141:300–304.
16.
Egerter SBraveman PMarchi K2002. Timing of insurance and use of prenatal care among low-income womenAm J Public Health92423-427. 16. Egerter S, Braveman P, Marchi K 2002 Timing of insurance and use of prenatal care among low-income women. Am J Public Health 92:423–427.
17.
Braveman PMarchi KSarnoff REgerter SRittenhouse D2003Promoting Access to Prenatal Care: Lessons from the California ExperienceThe Henry J. Kaiser Family FoundationWashington, DC. 17. Braveman P, Marchi K, Sarnoff R, Egerter S, Rittenhouse D 2003 Promoting Access to Prenatal Care: Lessons from the California Experience. The Henry J. Kaiser Family Foundation, Washington, DC.
18.
Pleis JRLethbridge-Cejku M2007. Summary Health Statistics for U.S Adults: National Health Interview Survey2006National Center for Health Statistics Vital and Health Statistics Series 10Atlanta, GA. 18. Pleis JR, Lethbridge-Cejku M 2007 Summary Health Statistics for U.S. Adults: National Health Interview Survey, 2006. National Center for Health Statistics Vital and Health Statistics Series 10, Atlanta, GA.
19.
American Thyroid Association (ATA)Guidelines Taskforce on Thyroid NodulesDifferentiated Thyroid Cancer; Cooper DSDoherty GMHaugen BRKloos RTLee SLMandel SJMazzaferri ELMcIver BPacini FSchlumberger MSherman SISteward DLTuttle RM2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid191167-1214. 19. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer; Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214.
20.
Wartofsky L2000. The thyroid nodule: pathogenesis, evaluation, risk of malignancyWartosfsky LThyroid Cancer: A Comprehensive Guide to Clinical ManagementHumana PressTotowa NJ3-9. 20. Wartofsky L 2000 The thyroid nodule: pathogenesis, evaluation and risk of malignancy. In: Wartosfsky L (ed) Thyroid Cancer: A Comprehensive Guide to Clinical Management, Humana Press, Totowa NJ. pp 3–9.
21.
Oertel Y2000. The thyroid nodule: fine needle aspirationWartosfsky LThyroid Cancer: A Comprehensive Guide to Clinical ManagementHumana PressTotowa NJ35-39. 21. Oertel Y 2000 The thyroid nodule: fine needle aspiration. In: Wartosfsky L (ed) Thyroid Cancer: A Comprehensive Guide to Clinical Management, Humana Press, Totowa NJ. pp 35–39.
22.
Owens GM2008. Gender differences in health care expenditures, resource utilization, and quality of careJ Manag Care Pharm142-6. 22. Owens GM 2008 Gender differences in health care expenditures, resource utilization, and quality of care. J Manag Care Pharm 14:2–6.
23.
Tarone REChu KC1996. Evaluation of birth cohort patterns in population disease ratesAm J Epidemiol14385-91. 23. Tarone RE, Chu KC 1996 Evaluation of birth cohort patterns in population disease rates. Am J Epidemiol 143:85–91.
Information & Authors
Information
Published In
Copyright
Copyright 2011, Mary Ann Liebert, Inc.
History
Published in print: February 2011
Published online: 29 January 2011
Published ahead of print: 27 December 2010
Topics
Authors
Disclosure Statement
The authors declare that no competing financial interests exist.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.